Ironwood Pharmaceuticals (IRWD) Competitors $1.10 -0.14 (-10.89%) As of 12:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRWD vs. ABBV, RIGL, ZBIO, MYGN, VSTM, EBS, LXRX, XOMA, CBIO, and VNDAShould you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include AbbVie (ABBV), Rigel Pharmaceuticals (RIGL), Zenas BioPharma (ZBIO), Myriad Genetics (MYGN), Verastem (VSTM), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "medical" sector. Ironwood Pharmaceuticals vs. Its Competitors AbbVie Rigel Pharmaceuticals Zenas BioPharma Myriad Genetics Verastem Emergent Biosolutions Lexicon Pharmaceuticals XOMA Royalty Crescent Biopharma Vanda Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Do institutionals & insiders hold more shares of IRWD or ABBV? 70.2% of AbbVie shares are held by institutional investors. 12.7% of Ironwood Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, IRWD or ABBV? Ironwood Pharmaceuticals has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Does the media refer more to IRWD or ABBV? In the previous week, AbbVie had 60 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 74 mentions for AbbVie and 14 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.03 beat Ironwood Pharmaceuticals' score of 0.74 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 49 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Do analysts rate IRWD or ABBV? Ironwood Pharmaceuticals currently has a consensus target price of $4.94, indicating a potential upside of 363.85%. AbbVie has a consensus target price of $214.95, indicating a potential upside of 1.03%. Given Ironwood Pharmaceuticals' higher possible upside, research analysts plainly believe Ironwood Pharmaceuticals is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ironwood Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14AbbVie 0 Sell rating(s) 6 Hold rating(s) 16 Buy rating(s) 4 Strong Buy rating(s) 2.92 Is IRWD or ABBV more profitable? AbbVie has a net margin of 6.45% compared to Ironwood Pharmaceuticals' net margin of -2.25%. AbbVie's return on equity of 699.66% beat Ironwood Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ironwood Pharmaceuticals-2.25% -2.46% 2.19% AbbVie 6.45%699.66%13.64% Which has stronger earnings & valuation, IRWD or ABBV? AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIronwood Pharmaceuticals$351.41M0.49$880K-$0.05-21.30AbbVie$56.33B6.67$4.28B$2.10101.32 SummaryAbbVie beats Ironwood Pharmaceuticals on 15 of the 17 factors compared between the two stocks. Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRWD vs. The Competition Export to ExcelMetricIronwood PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.99M$2.53B$5.76B$9.84BDividend YieldN/A48.51%6.66%4.49%P/E Ratio-21.3022.5582.8926.42Price / Sales0.49527.81503.85163.22Price / Cash26.6926.3325.7028.92Price / Book-0.566.8810.856.51Net Income$880K$32.94M$3.28B$266.13M7 Day Performance-19.32%-0.11%-0.31%-1.18%1 Month Performance41.91%5.45%6.66%3.36%1 Year Performance-78.53%-1.53%50.01%23.58% Ironwood Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRWDIronwood Pharmaceuticals4.1564 of 5 stars$1.11-10.9%$4.94+347.1%-75.1%$179.49M$351.41M-22.10220News CoverageAnalyst RevisionGap DownABBVAbbVie4.6939 of 5 stars$207.58-1.4%$214.95+3.6%+7.1%$372.04B$56.33B98.8555,000Trending NewsRIGLRigel Pharmaceuticals2.7862 of 5 stars$40.74-1.8%$38.20-6.2%+201.9%$744.39M$267.92M7.53160Positive NewsShort Interest ↓Gap UpZBIOZenas BioPharma1.6582 of 5 stars$16.56-3.2%$36.67+121.4%N/A$720.09M$5M-4.66N/AMYGNMyriad Genetics3.4965 of 5 stars$5.89-2.2%$12.45+111.5%-75.2%$560.13M$837.60M-1.382,700Positive NewsVSTMVerastem3.0819 of 5 stars$8.98-1.1%$13.29+47.9%+292.6%$558.83M$10K-2.7450EBSEmergent Biosolutions4.8157 of 5 stars$9.17-0.7%$14.33+56.3%+6.5%$492.43M$1.04B3.742,420Positive NewsAnalyst ForecastLXRXLexicon Pharmaceuticals2.2925 of 5 stars$1.13-5.0%$3.23+185.4%-32.9%$432.45M$31.08M-3.42140News CoverageAnalyst ForecastXOMAXOMA Royalty3.7335 of 5 stars$33.77-1.3%$69.50+105.8%+20.0%$413.40M$28.49M-21.7910Positive NewsCBIOCrescent Biopharma3.7476 of 5 stars$14.70-2.4%$25.60+74.1%N/A$294.42MN/A-0.4250VNDAVanda Pharmaceuticals4.1268 of 5 stars$4.61-2.9%$16.50+257.9%-7.1%$280.67M$198.77M-4.08290 Related Companies and Tools Related Companies AbbVie Alternatives Rigel Pharmaceuticals Alternatives Zenas BioPharma Alternatives Myriad Genetics Alternatives Verastem Alternatives Emergent Biosolutions Alternatives Lexicon Pharmaceuticals Alternatives XOMA Royalty Alternatives Crescent Biopharma Alternatives Vanda Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRWD) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
